Monthly Archives: February 2011

The Pain in Spain

By Guest Blogger | Published: February 16, 2011
The pain of the Spanish drug-spending squeeze extends way beyond the plain, says Reflector. The cries of anguish at Spanish drug-spending squeezes are coming not only from Madrid, but from many of the autonomous regions around the periphery of the country too. After almost a decade of continual disruption and downward pressure on pricing, the medicines industry [...]
Posted in Europe, Global, Guest Blog, Regulatory | Tagged , , , | 2 Comments

Medical Technology Innovation—Less is More

By Jennifer Ringler | Published: February 15, 2011
The latest Medical Technology Innovation Scorecard Report from PwC reveals that the future of medical technology focuses on less—lower costs, smaller medical devices, less complicated products and services—all resulting in more ROI. The report predicts that emerging countries may be more poised to deliver on such a philosophy than the traditional Big Guns such as [...]
Posted in Strategy | 4 Comments

Emerging Pharma Leaders 2011

By Julian Upton | Published: February 14, 2011
Pharm Exec is looking for the fresh faces of pharma leadership. And we’d like your input! Tell us who you think should receive Pharmaceutical Executive’s 2011 Emerging Pharma Leadership Award. As the pharma industry faces a turbulent road ahead—the patent cliff, rising world players, US healthcare reform, etc.—the previous ways of doing business just won’t cut [...]
Posted in Strategy | Tagged | Leave a comment

Prolia: Runner Up in Pharm Exec Brand of the Year

By Guest Blogger | Published: February 9, 2011
This month, Pharm Exec magazine presents its Brand of the Year. Here, Brittany Agro profiles one of the runners-up, Amgen’s osteoporosis treatment, Prolia. A joint meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, held June 2005 in Geneva, Switzerland, revealed promising developments for more effective treatments in bone heath—specifically geared [...]
Posted in healthcare | Tagged , , , | 2 Comments

Delay to Bribery Act: Breathing Space for UK Pharma?

By Julian Upton | Published: February 9, 2011
Pharma companies anxious about the implications of the imminent UK Bribery Act — which is set to take a hard line on corruption that some might regard as draconian — may be relieved to hear that it has been delayed again. Earlier this month the UK Ministry of Justice announced that its implementation, which was [...]
Posted in Emerging Markets, Europe, Global, Regulatory | 1 Comment